There are 2789 resources available
1095TiP - Daromun, a dermato-oncology drug in development for stage III and IV melanoma and non-melanoma skin cancers: A clinical overview
Presenter: Katharina Kähler
Session: ePoster Display
1102P - The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses
Presenter: Philippe Ruszniewski
Session: ePoster Display
1103P - 177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase II prospective clinical trials
Presenter: Alberto Bongiovanni
Session: ePoster Display
1104P - Functional imaging and clinical outcomes in grade 3 neuroendocrine tumors (NETs G3): A single-center retrospective analysis
Presenter: Alice Laffi
Session: ePoster Display
1105P - Predictive factors of adverse events onset in GEPNET patients treated with PRRT
Presenter: Federica Scalorbi
Session: ePoster Display
1106P - Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms
Presenter: Timothy Price
Session: ePoster Display
1107P - Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
Presenter: Jaume Capdevila
Session: ePoster Display
1108P - Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas
Presenter: Baddar Pervaiz Butt
Session: ePoster Display
1109P - The psychological impact of COVID-19 pandemic on patients with NETs: Between resilience and vulnerability
Presenter: Eleonora Lauricella
Session: ePoster Display
1110P - COVID-19 pandemic impact on healthcare professionals treating patients with neuroendocrine tumors (NET): An international NET CONNECT survey
Presenter: Jorge Hernando
Session: ePoster Display